Jiangsu Nhwa Pharmaceutical Co., Ltd. Class ASZSE: 002262

Jiangsu Nhwa Pharmaceutical: Q3 2025 revenue and net profit rose 5.70% and 3.67% year-over-year, respectively

· Issued by Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Q3 2025 revenue grew 5.70% year-over-year to ¥1.46 billion, with net profit up 3.67% to ¥405.55 million. Year-to-date revenue and net profit rose 7.85% and 8.42%, respectively, while cash flow and equity remained strong.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

All Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A news releases